Tibet Aim Pharm Inc (002826.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE100002C39

Price
16.08 CNY
Market cap
3.07 bn CNY
P/E (2025)
33.12
P/S (2025)
4.82
Dividend yield
0.93 %
Net margin
14.55 %
Return on equity (ROE)
11.35 %
Return on assets (ROA)
9.10 %

Tibet Aim Pharm Inc financials

Fiscal year20242025
Revenue651.88 m CNY636.27 m CNY
Gross profit446.34 m CNY522.46 m CNY
Operating income61.50 m CNY98.60 m CNY
EBIT60.89 m CNY114.67 m CNY
Net income45.93 m CNY92.58 m CNY
Diluted EPS – continuing operations0.25 CNY0.49 CNY

Full history since 2013, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Tibet Aim Pharm Inc

Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company's products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; medicines for gynecology and obstetrics; and Gualoupi injection, Nalmefene hydrochloride injection, and Carbetocin injection. It also provides Domperidone tablets for treatment of indigestion, abdominal bloating, belching, nausea, vomiting, and abdominal distension and pain; Montmorillonite powder for chronic diarrhea; and Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotics, antiallergic, and digestive systems. Tibet AIM Pharm. Inc. was founded in 2003 and is based in Lhasa, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.